Filippo Alongi

Ospedale Sacro Cuore Don Calabria

Papers

2

Total Citations

59

H-Index

2

About

Filippo Alongi is a leading figure in radiation oncology, whose research centers on optimizing radiotherapy techniques and treatment sequencing for genitourinary and gastrointestinal cancers. His major contributions include pioneering the use of moderate hypofractionated volumetric modulated arc therapy with daily image guidance (VMAT-IGRT) for postprostatectomy patients, demonstrating its feasibility and favorable acute toxicity profile in a seminal 2017 study (45 citations). This work has helped shape modern prostate cancer management by enabling shorter, more precise treatment courses. Alongi also leads the multicenter TiMiSNAR trial, a randomized controlled study investigating the optimal timing between neoadjuvant chemoradiotherapy and minimally-invasive surgery for rectal cancer. By comparing standard 8-week versus prolonged 12-week intervals, his research addresses a critical clinical question about maximizing pathologic complete response rates. His work bridges technological innovation with practical clinical outcomes, influencing international guidelines. With a career marked by high-impact studies and collaborative trials, Alongi continues to advance personalized, evidence-based radiotherapy protocols that improve patient quality of life and treatment efficacy.

Research Focus

Key Achievements

2
H-Index
2
Papers
59
Total Citations
30
Avg Citations/Paper
🏆 Most Cited Paper
Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity
45 citations · 2017
📈 Most Prolific Year: 2017 (1 Papers)
🤝 Key Collaborators: 47
🏛 Institutions: Ospedale Sacro Cuore Don Calabria

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago